Insights
The peptide market just moved from the grey zone into regulated compounding. Here is what happened, who said what, and what it means for a business with a front door.
Policy, Oct 28, 2026
HHS issued an enforcement discretion policy covering BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. State-licensed pharmacies and physicians may compound them under ten conditions, including FDA-registered sourcing, certificates of analysis, single-ingredient products and MedWatch reporting.
Source: The Hill
Legal view
Healthcare law firm Hyman, Phelps & McNamara reads the policy as interim: it does not put the peptides on the 503A bulks list, does not approve any drug, and asks more of compounders on testing, sourcing and reporting than current practice. Fifteen years of rulemaking have moved only six substances onto the list.
Source: FDA Law Blog
Industry reaction
The Alliance for Pharmacy Compounding called sourcing the real issue, since patients were already buying from illicit suppliers. The Partnership for Safe Medicines said FDA scientists had recommended against the vote and questioned conflicts on the advisory committee. Both are right that the status quo was a grey market.
Source: The Hill
The vote, July 2026
BPC-157, KPV and TB-500 were recommended 8 to 6 with one abstention, MOTS-c 7 to 5 with two. DSIP was not recommended. FDA's own briefing documents had concluded the evidence was insufficient. A recommendation is advisory; the October policy is what changed practice.
Source: AJMC
Enforcement
Through 2026 FDA kept writing to online sellers of research-use-only peptides, naming retatrutide, tesamorelin, PT-141 and the GLP-1s. The policy covers six peptides compounded under prescription; it does nothing for a vial shipped from a website.
Source: FDA Law Blog
Next
GHK-Cu, LL-37, dihexa, melanotan II and PEG-MGF are scheduled for PCAC review. If the October pattern holds, a favourable vote would be followed by a further HHS decision rather than immediate availability.
Source: FDA Law Blog
External reporting and commentary describe public regulatory actions, not any Local Healthcare program's results.